In many skilled nursing facilities, speech-language pathologists are brought in to address individual issues. But an alternative framing is more powerful.

Collaboration expands access to innovative gait rehabilitation and fall prevention solutions, combining technology and ...

Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial ...

Hospitals and cancer centers that are launching cell and gene therapy programs need more than scientific breakthroughs to succeed. Delivering these therapies safely and efficientl ...

Designing to protect its people improves oncology staff safety and patient comfort at Tennessee Oncology’s $120M facility with integrated ...

Our position in American pharmaceutical company, Eli Lilly & Company (1.8%), was a top contributor to relative returns during the fourth quarter.

THE WOODLANDS, Texas, Feb. 24, 2026 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a strategic collaboration ...

SHANGHAI, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ...

Recent transactions make clear that large pharmaceutical companies now view rare disease as a core area for sustained growth, rather than episodic deal-making. BioMarin’s acquisition of Amicus ...

Louisiana’s first Hybrid Doctor of Physical Therapy program addresses critical workforce needs through alignment with ...

Rare disease drug developers struggle to survive in a biopharma investment market that prioritizes large patient populations. Initiatives like the Orphan Therapeutics Accelerator are attempting to ...

However, traditional clinical trial designs are often ill-suited for rare disease research with common challenges including ...